janetlucyy - Tumblr blog

[janetlucyy]

Get (Gefitinib) Iressa Delivered Discreetly to Your Doorstep

Experience convenience and privacy with our discreet of (Gefitinib) Iressa delivery service. Say goodbye to long store lines and enjoy the ease of receiving your prescriptions at your doorstep. Our trustworthy and confidential delivery confirms your health needs are met without compromising your privacy. Embrace a hassle-free approach to managing your well-being.

[janetlucyy]

Long-term complete response to gefitinib after treatment termination in a patient with recurrent post-operative EGFRmutated lung adenocarcinoma: case report and literature review

Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is highly sensitive to EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, few cases of advanced NSCLC completely cured by EGFR-TKIs have been reported. We present an extremely rare case of lung adenocarcinoma that was completely cured by gefitinib administration. A 36-year-old Japanese woman was diagnosed with clinical Stage IIIB (T2N3M0) lung adenocarcinoma originating from the left upper lobe in April 2006. After the two cycles of chemotherapy, it was down-staged to ycStage IA (T1N0M0). She underwent a thoracotomy with left upper lobectomy, pulmonary angioplasty, and mediastinal nodal dissection in July 2006 [ypStage IIIA (T3N1M0)].

Eighteen months later, she was found to have lymphadenopathy of the right supraclavicular nodes. Fine needle aspiration cytology of the lymph node indicated adenocarcinoma. She started gefitinib therapy for recurrent lung cancer with EGFR mutation (exon 19 deletion) in January 2008. Four months afterward, computed tomography (CT) showed her right supraclavicular nodes had shrunk dramatically. Treatment with gefitinib was continued. Thereafter, no disease progression was observed throughout her approximately 8-year gefitinib treatment, and gefitinib was terminated in November 2016. Although the patient received no other treatment, she has suffered no recurrence in the 4 years since. A review of the literature, including our case, is also presented.

[janetlucyy]

The gefitinib efitinib story

Gefitinib (Iressa, ZD1839, AstraZeneca Japan) was approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) in July 2002 for the treatment of inoperable or recurrent non-small cell lung cancer (NSCLC). In Japan, up until the end of January 2003, approximately 23 500 people had received gefitinib and 183 deaths had been attributed to the drug. Acute lung disease and/or interstitial pneumonitis were implicated in 173 deaths. In this article we shall give a brief description of gefitinib, an outline of the experience with this drug in Japan and in Western countries, and also our opinion on what should be learnt from this story.

[janetlucyy]

About Gefitinib (Iressa)

Gefitinib is a tyrosine kinase inhibitor. It works by targeting and blocking epidermal growth factor receptor (EGFR) tyrosine kinase. In some cancers, this receptor is overactive, causing cells to grow and divide too fast. By inhibiting EGFR, gefitinib prevents the uncontrolled growth of cells that contributes to tumor growth. Your oncology team will test your tumor for this abnormality, which must be present in order to receive the medication.

[janetlucyy]

Environmental Risk Assessment Data Gefitinib

https://www.astrazeneca.com/content/dam/az/our-company/Sustainability/2017/gefitinib.pdf

Gefitinib is an epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor that acts to block signals for cancer cell growth and survival in non-small cell lung cancer.

The intended use of gefitinib is likely to result mainly in metabolites and, to a lesser extent, the parent compound entering the environment, mainly via faeces. The metabolites are generally less pharmacologically active than the parent. The parent compound excreted represents approximately 11% of the given dose.

Based on the physico-chemical and fate properties of gefitinib, it is predicted that any active moiety present in domestic sewage will be partitioned partly into the sludge phase during wastewater treatment. Gefitinib is not readily biodegradable. In the aquatic environment, there is evidence that the substance will partition into aquatic sediments.

The Predicted Environmental Concentration (PEC) / Predicted No Effect Concentration (PNEC) ratio is 6.31 x 10-4 , which means use of Gefitinib is predicted to present an insignificant risk to the environment.

[janetlucyy]

Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center

Patients with non-small cell lung cancer are deemed incurable, but they may derive benefit from palliative chemotherapy. Unfortunately, however, life expectancy is low in such cases and may be hampered by chemotherapy-related toxicity.

Gefitinib (Iressa®, ZD1839) is a tyrosine kinase inhibitor that targets the intracellular domain of the epidermal growth factor receptor (EGFR), thereby blocking signal transduction pathways that are implicated in the proliferation and survival of cancer cells.1 Phase 1 trials on gefitinib defined a range of doses from 250 to 500 mg to be used in phase II studies.2 The toxicity observed in Phase I studies was mild and consisted mainly of skin rash and diarrhea.2 Phase II studies on patients with advanced previously-treated non-small cell lung cancer showed similar results for both 250 and 500 mg daily dosages.3 In these patients an objective response rate of between 10 and 20% has consistently been achieved and around an additional 40% of patients have derived clinical benefit due to disease stabilization. Furthermore, this clinical benefit has translated into improved quality of life for these patients.